Age-related plasma reference ranges for two heparin- Vinding proteins - Vitronectin and platelet factor 4

International Journal of Laboratory Hematology

Volumn 31, Issue 6, 2009, Pages 683-687

  Newall, F ^a,b,c   Johnston, L ^a,b,c   Ignjatovic, V ^a,c   Summerhayes, R ^a,c   Monagle, P ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Platelet factor 4; Reference ranges; Unfractionated heparin; Vitronectin

Indexed keywords

HEPARIN; THROMBOCYTE FACTOR 4; VITRONECTIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; DRUG BINDING; HUMAN; NORMAL HUMAN; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REFERENCE VALUE; SCHOOL CHILD; BLOOD; INFANT; METABOLISM; PROTEIN BINDING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HEPARIN; HUMANS; INFANT; PLATELET FACTOR 4; PROTEIN BINDING; VITRONECTIN;

EID: 74049157682     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2008.01107.x     Document Type: Article

References (21)

1. Andrew M., Vegh P., Johnston M., Bow- ker J., Ofosu F. &Mitchell L. (1992) Maturation of the hemostatic system during childhood. Blood 80, 1988-2005.
2. Bittorf S., Williams E. &Mosher D. (1993) Alteration of Vitronectin: Characterization of changes induced by treatment with urea. The Journal of Biological Chemistry 268, 24838-24846.
3. Conlan M., Tomasini B., Schultz R. &Mosher D. (1988) Plasma Vitronectin Polymorphism in Normal Subjects and Patients with Disseminated Intravascular Coagulation. Blood 72, 185-190.
4. Dawes J., Smith R. &Pepper D. (1978) The release, distribution and clearance of human (f-thromboglobulin and platelet factor 4. Thrombosis Research 12, 851-861.
5. Denton J., Lane D., Thunberg L., Slater A. &Lindahl U. (1983) Binding of platelet- factor-4 to heparin oligosaccharides. Biochemical Journal 209, 455-466.
6. Francois P., Preissner K., Herrmann M., Haugland R., Vaudaux P., Lew D. &Krause K.-H. (1999) Vitronectin interaction with glycosaminoglycans. The Journal of Biological Chemistry 274, 37611-37619.
7. Gosk-Bierska I., Adamiec R., Alexewicz P. &Wysokinski W. (2002) Coagulation in diabetic and non-diabetic claudicants. International Angiology 2, 128-133.
8. Ignjatovic V., Furmedge J., Newall F., Chan A., Berry L., Fong C., Cheng K. &Monagle P. (2006a) Age-related differences in heparin response. Thrombosis Research 118, 741-745.
9. Ignjatovic V., Summerhayes R., Than J., Gan A., &Monagle P. (2006b) Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. Journal of Thrombosis and Haemostasis 4, 2280-2282.
10. Ignjatovic V., Summerhayes R., Gan A., Than J., Chan A., Cochrane A., Bennet M., Shann F., Lane G., Ross-Smith M. &Monagle P. (2007) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate?. Thrombosis Research 120, 347-351.
11. Lane D., Denton J., Flynn A., Thunberg L. &Lindahl U. (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet-fac- tor-4. Biochemical Journal 218, 725-732.
12. Lane D., Pejler G., Flynn A., Thompson E. &Lindahl U. (1986) Neutralization of heparin-related saccharides by histidine- rich glycoprotein and platelet factor-4. The Journal of Biological Chemistry 261, 3980-3986.
13. Lane D., Flynn A., Pejler G., Lindahl U., Choay J. &Preissner K. (1987) Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. The Journal of Biological Chemistry 262, 16343-16348.
14. Liang O., Rosenblatt S., Chhatwal G. &Preissner K. (1997) Identification of novel heparin-binding domains of vitro- nectin. FEBS Letters 407, 169-172.
15. Monagle P., Barnes C., Ignjatovic V., Furmedge J., Newall F., Chan A., DeRosa L., Hamilton S., Ragg P., Robinson S., Auldist A., Crock C. &Rowlands S.(2006) Developmental haemostasis: impact for clinical haemostasis laboratories. Thrombosis and Haemostasis 95, 362-372.
16. Moore S., Pepper D. &Cash J. (1975) Platelet anti-heparin activity: the isolation and characterization of platelet-factor-4 released from thrombin aggregated washed human platelets and its dissociated into subunits and the isolation of membrane-bound antiheparin activity. Biochimica et Biophysica Acta 379, 370-384.
17. Newall F., Barnes C., Ignjatovic V. &Mona- gle P. (2003) Heparin-induced thrombo- cytopenia in children. Journal of Paediatrics and Child Health 39,289-292.
18. Podor T., Campbel S., Chindemi P., Fou- lon D., Farrell D., Walton P., Wietz J. &Peterson C. (2002) Incorporation of vitronectin into fibrin clots. The Journal of Biological Chemistry 277, 7520-7528.
19. Preissner K. &Muller-Berghaus G. (1986) S protein modulates the heparin-cata- lyzed inhibition of thrombin by anti- thrombin III. European Journal of Biochemistry 156, 645-650.
20. Preissner K. &Muller-Berghaus G. (1987) Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. The Journal of Biological Chemistry 262, 12247-12253.
21. Young J., Kisker C. &Doty D. (1978) Adequate anticoagulation during cardio- pulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Annals of Thoracic Surgery 26, 231-240.